Simple visualization method for the c.577del of erythropoietin variant: CRISPR/dCas9‐based single nucleotide polymorphism diagnosis
Drug Testing and Analysis · 2024
DOI: 10.1002/dta.3438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2024. Verfasst von Joon-Yeop Yi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doping Control Center, Korea Institute of Science and Technology, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Erythropoietin, Polymorphism, Single Nucleotide, Doping in Sports, CRISPR-Cas Systems. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Institute of Science and Technology.
Abstract (Originalsprache)
One of the single nucleotide polymorphisms (SNPs) in human erythropoietin ( hEPO ), the c.577del variant, can produces 26 amino acids longer than the wild‐type hEPO, posing a risk of misinterpretation in routine doping analysis. To prevent this, the World Anti‐Doping Agency (WADA) included a procedure for reporting the sequencing results regarding the presence or absence of SNPs for suspected cases in the new version of the technical document for recombinant EPO in 2022. However, it is very expensive for anti‐doping laboratories to purchase a gene sequencing analyzer, which costs hundreds of thousands of dollars, and only a few companies provide specific gene sequencing services with accredited certification. Therefore, in this study, we developed a simple visualization method for the c.577del of the EPO variant at the gene level. The gene fragment of the EPO gene, including c.577del, was amplified using a fast polymerase chain reaction (PCR), and the PCR products were incubated with the clustered regularly interspaced short palindromic repeats (CRISPR)/deadCas9 system using variant‐specific single‐guide RNA (sgRNA). This ribonucleoprotein complex binds specifically to the EPO variant gene fragment, causing a band shift on native‐PAGE. We designed 4 sgRNAs that can bind only to the EPO variant or wild‐type gene. In addition, an electrophoretic mobility shift assay on a gel demonstrated that one of the sgRNAs had a high level of specificity. Consequently, the c.577del variant was selectively detected by visualizing the target fragment of the gene on the gel within 3 h using only 3 μl of the whole blood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doping Control Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
- Interdisciplinary Program of Bioengineering, Seoul National University, Seoul, Republic of Korea.
- Institute of Molecular Biology and Genetics, Seoul National University, Seoul, Republic of Korea.
- Bio-Max/N-Bio Institute, Seoul National University, Seoul, Republic of Korea.
- School of Chemical and Biological Engineering, Seoul National University, Seoul, Republic of Korea.
- Institute for Sustainable Development (ISD), Seoul National University, Seoul, Republic of Korea.
ORCID-Profile: Hophil Min, Junghyun Son, Changmin Sung
Förderung
- Korea Institute of Science and Technology
Zitieren
APA
Yi, J. Y., Kim, M., Jeon, M., Min, H., Kim, B. G., Son, J., & Sung, C. (2024). Simple visualization method for the c.577del of erythropoietin variant: CRISPR/dCas9‐based single nucleotide polymorphism diagnosis. Drug Testing and Analysis. https://doi.org/10.1002/dta.3438
Vancouver
Yi JY, Kim M, Jeon M, Min H, Kim BG, Son J, et al. Simple visualization method for the c.577del of erythropoietin variant: CRISPR/dCas9‐based single nucleotide polymorphism diagnosis. Drug Testing and Analysis. 2024. doi:10.1002/dta.3438
BibTeX
@article{Yi2024,
author = {Yi, Joon-Yeop and Kim, Minyoung and Jeon, Mijin and Min, Hophil and Kim, Byung-Gee and Son, Junghyun and Sung, Changmin},
title = {Simple visualization method for the c.577del of erythropoietin variant: CRISPR/dCas9‐based single nucleotide polymorphism diagnosis},
journal = {Drug Testing and Analysis},
year = {2024},
doi = {10.1002/dta.3438}
}
EUVIMED